SillaJen

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma SillaJen starts US trial of anti-cancer drug from Basilea

SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Ba...

Corporate restructuring M2N to sell 52% stake in Chinese automotive parts company DKCA

M2N( DK D&I Co. ), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its maj...

Bio & Pharma S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug

South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swis...

Bio & Pharma SillaJen shares jump as exchange maintains listing, allows resumed trade

Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the...

Fraud scandals Scandal-hit SillaJen faces higher delisting risk

South Korea's SillaJen Inc., once the largest stock on Kosdaq by market value, faces a higher risk of being kicked out of the country's junior stock...